Endocrine Abstracts

The present study investigated the vasorelaxant effects of sitagliptin, which is a dipeptidyl peptidase-4 (DPP-4) inhibitor in aortic rings pre-contracted with phenylephrine (Phe). Sitagliptin induced vasorelaxation in a concentration-dependent manner but the inhibition of voltage-dependent K+ (Kv) channels by pretreatment with 4-aminopyridine (4-AP) effectively reduced this effect. By contrast, the inhibition of inward rectifier K+ (Kir) channels by pret...

In this study, we used the phenylephrine-precontracted aortic ring preparation to investigate the mechanisms underlying the vasorelaxant effect of linagliptin. We found that linagliptin induced vasorelaxation in a dose-dependent manner. The vasorelaxant effect of linagliptin was not changed by the removal of the endothelium, or by pre-treatment with a NO synthase inhibitor (L-NAME) or a small-conductance Ca2+-dependent K+ channel inhibitor (apamin). Moreo...

The vasodilatory effects of the meglitinide class of anti-diabetic drug, mitiglinide in phenylephrine (Phe)-pre-contracted aortic rings were investigated. Mitiglinide concentration-dependently induced vasodilation. Administration of the large-conductance Ca2+-dependent K+ (BKCa) channel inhibitor paxilline, inward rectifier K+ (Kir) channel inhibitor Ba2+, and ATP-dependent K+ (KATP) channel inhibitor...

In this study, we explored vildagliptin-induced vasorelaxation and its related signaling mechanisms using phenylephrine induced pre-contracted rabbit aortic rings. Vildagliptin induced vasorelaxation in a dose-dependent fashion. Pre-treatment with the large-conductance Ca2+-dependent K+ channel inhibitor paxilline, ATP-dependent K+ channel inhibitor glibenclamide and inward rectifier K+ channel inhibitor Ba2+ did not chang...